‘Oxford/AstraZeneca vaccine behind lower Covid-19 deaths in UK’

Expert says, although RNA jabs produce more obvious and rapid jump in antibody levels in lab tests, other vaccines may be better at priming another part of the immune system – cellular immunity

Britain’s early deployment of the Oxford/AstraZeneca vaccine to protect against COVID-19 may be responsible for the country’s lower death rates compared to other European countries, a UK vaccines expert has said.

Dr Clive Dix, former chairman of the UK’s Vaccine Task Force, told the ‘Daily Telegraph’ that the Oxford/AstraZeneca vaccine – manufactured and administered in India as Covishield – may offer stronger long-term protection against severe COVID-19 and death.

“If you look across Europe, with the rise in cases, there’s also a corresponding lagged rise in deaths, but not in the UK, and we have to understand that,” said Dr Dix. “I personally believe that’s because most of our vulnerable people were given the AstraZeneca vaccine,” he said.

According to Our World in Data, a website run by the University of Oxford, the UK has 1.7 daily deaths from COVID per million people. In comparison, the European Union (EU) as a whole has almost four.

The key, Dix believes, is that although the RNA jabs such as Pfizer/BioNTech produce a more obvious and rapid jump in antibody levels in lab tests, other vaccines may be better at priming another part of the immune system called cellular immunity. This includes various forms of T cells, including those that destroy infected cells, and also memory cells, ensuring a person can fight off an infection several years after they are first exposed to it. They are slower to react than antibodies and do not prevent infection, but halt the pathogen in its tracks, making it harder for the virus to cause damage.

“We’ve seen early data that the Oxford jab produces a very durable cellular response and if you’ve got a durable cellular immunity response then they can last for a long time. It can last for life in some cases,” Dix told the newspaper. The only notable difference, according to him, between UK and Europe’s vaccine rollout was the approach to the Oxford/AstraZeneca jab. European regulators approved use of the vaccine long after the UK  rolled it out among its older age groups at the end of last year. 

New York sees four-fold rise in pediatric hospitalisations

Amid the rapid spread of the Omicron variant in the US, New York City has seen a four-fold rise in children being hospitalised for COVID-19 since early December. The New York State Health Department said the increase was observed in children aged 18 and under beginning the week of December 5 through the current week, ABC News reported. 

Australia’s most populous state reports 1st omicron death

Australia’s New South Wales state reported more than 6,000 new COVID-19 cases on Monday and confirmed its first death from the omicron variant. The fatal case was identified as a man in his 80s who was infected at an aged care facility in western Sydney. He was fully vaccinated but had health conditions.

Flight to Shanghai turned back

Delta Air Lines said Monday that new pandemic-related cleaning requirements at a Shanghai airport were why a recent flight was turned back from Seattle in midair. A statement said the  mandates at Shanghai Pudong International Airport “require significantly extended ground time and are not operationally viable for Delta”. 

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!